NuCana plc to Present at the Jefferies 2017 London Healthcare Conference
November 02, 2017 08:00 ET
|
NuCana plc
EDINBURGH, United Kingdom, Nov. 02, 2017 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer...
NuCana plc Announces Closing of Initial Public Offering of ADSs and Exercise of Underwriters’ Option to Purchase Additional ADSs
October 02, 2017 13:39 ET
|
NuCana plc
EDINBURGH, United Kingdom, Oct. 02, 2017 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer...
NuCana plc Announces Pricing of Initial Public Offering
September 27, 2017 21:36 ET
|
NuCana BioMed Limited
EDINBURGH, United Kingdom, Sept. 27, 2017 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer...
NuCana Announces Interim Data from First-In-Human Study of Transformative Anti-Cancer Agent, NUC-3373
September 13, 2017 07:00 ET
|
NuCana BioMed Limited
EDINBURGH, United Kingdom, Sept. 13, 2017 (GLOBE NEWSWIRE) -- NuCana plc announced the presentation of interim first-in-human data from a Phase 1 clinical study of NUC-3373, its ProTide...
NuCana Announces Positive Results of NUC-1031 (Acelarin®) in Advanced Ovarian Cancer at ESMO 2017
September 12, 2017 07:00 ET
|
NuCana BioMed Limited
EDINBURGH, United Kingdom, Sept. 12, 2017 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company developing a portfolio of novel anti-cancer medicines called ProTides®, announced...